Checkpoint Capital L.P. Argenx Se Transaction History
Checkpoint Capital L.P.
- $215 Billion
- Q2 2025
A detailed history of Checkpoint Capital L.P. transactions in Argenx Se stock. As of the latest transaction made, Checkpoint Capital L.P. holds 149,977 shares of ARGX stock, worth $120 Million. This represents 38.52% of its overall portfolio holdings.
Number of Shares
149,977
Previous 115,000
30.41%
Holding current value
$120 Million
Previous $68.1 Billion
21.46%
% of portfolio
38.52%
Previous 37.34%
Shares
6 transactions
Others Institutions Holding ARGX
# of Institutions
491Shares Held
28.3MCall Options Held
370KPut Options Held
211K-
Price T Rowe Associates Inc Baltimore, MD4.98MShares$3.98 Billion0.31% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI2.79MShares$2.23 Billion2.84% of portfolio
-
Janus Henderson Group PLC London, X02.57MShares$2.05 Billion0.73% of portfolio
-
Capital World Investors Los Angeles, CA1.95MShares$1.56 Billion0.16% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.18MShares$940 Million11.81% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $44.3B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...